New application of epiberberine

The invention discloses novel application of epiberberine and an experimental method for inhibiting osteoclast differentiation induced by breast cancer cells. It is proved for the first time that epiberberine cannot inhibit proliferation of osteoclast precursor cells at a high concentration (25 [mu]...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZHANG FUMING, ZHANG XUENING, YANG YANCHAO, LIU JIACHEN, LIU BEIJIA, SHI MEINA, WEI CHENGMING, LIN, WAN-JIUN, MA WENZHE, HUANG ZIFENG, WANG ZI
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZHANG FUMING
ZHANG XUENING
YANG YANCHAO
LIU JIACHEN
LIU BEIJIA
SHI MEINA
WEI CHENGMING
LIN, WAN-JIUN
MA WENZHE
HUANG ZIFENG
WANG ZI
description The invention discloses novel application of epiberberine and an experimental method for inhibiting osteoclast differentiation induced by breast cancer cells. It is proved for the first time that epiberberine cannot inhibit proliferation of osteoclast precursor cells at a high concentration (25 [mu] M), and the epiberberine has high biological safety. In addition, epiberberine has a remarkable inhibition effect on osteoclast formation induced by breast cancer and osteolysis induced by metastatic breast cancer. 本发明公开了表小檗碱的新用途以及抑制乳腺癌细胞诱导破骨细胞分化的实验方法。本发明首次证明表小檗碱在较高浓度时(25μM)不会抑制破骨细胞前体细胞的增殖,其具有较高的生物安全性。另外,表小檗碱对乳腺癌诱导破骨细胞形成、以及转移性乳腺癌诱导的骨溶解具有显著的抑制作用。
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN116803390A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN116803390A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN116803390A3</originalsourceid><addsrcrecordid>eNrjZJD3Sy1XSCwoyMlMTizJzM9TyE9TSC3ITEotAqLMvFQeBta0xJziVF4ozc2g6OYa4uyhm1qQH59aXJCYnJqXWhLv7GdoaGZhYGxsaeBoTIwaACWUJOM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>New application of epiberberine</title><source>esp@cenet</source><creator>ZHANG FUMING ; ZHANG XUENING ; YANG YANCHAO ; LIU JIACHEN ; LIU BEIJIA ; SHI MEINA ; WEI CHENGMING ; LIN, WAN-JIUN ; MA WENZHE ; HUANG ZIFENG ; WANG ZI</creator><creatorcontrib>ZHANG FUMING ; ZHANG XUENING ; YANG YANCHAO ; LIU JIACHEN ; LIU BEIJIA ; SHI MEINA ; WEI CHENGMING ; LIN, WAN-JIUN ; MA WENZHE ; HUANG ZIFENG ; WANG ZI</creatorcontrib><description>The invention discloses novel application of epiberberine and an experimental method for inhibiting osteoclast differentiation induced by breast cancer cells. It is proved for the first time that epiberberine cannot inhibit proliferation of osteoclast precursor cells at a high concentration (25 [mu] M), and the epiberberine has high biological safety. In addition, epiberberine has a remarkable inhibition effect on osteoclast formation induced by breast cancer and osteolysis induced by metastatic breast cancer. 本发明公开了表小檗碱的新用途以及抑制乳腺癌细胞诱导破骨细胞分化的实验方法。本发明首次证明表小檗碱在较高浓度时(25μM)不会抑制破骨细胞前体细胞的增殖,其具有较高的生物安全性。另外,表小檗碱对乳腺癌诱导破骨细胞形成、以及转移性乳腺癌诱导的骨溶解具有显著的抑制作用。</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230926&amp;DB=EPODOC&amp;CC=CN&amp;NR=116803390A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230926&amp;DB=EPODOC&amp;CC=CN&amp;NR=116803390A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHANG FUMING</creatorcontrib><creatorcontrib>ZHANG XUENING</creatorcontrib><creatorcontrib>YANG YANCHAO</creatorcontrib><creatorcontrib>LIU JIACHEN</creatorcontrib><creatorcontrib>LIU BEIJIA</creatorcontrib><creatorcontrib>SHI MEINA</creatorcontrib><creatorcontrib>WEI CHENGMING</creatorcontrib><creatorcontrib>LIN, WAN-JIUN</creatorcontrib><creatorcontrib>MA WENZHE</creatorcontrib><creatorcontrib>HUANG ZIFENG</creatorcontrib><creatorcontrib>WANG ZI</creatorcontrib><title>New application of epiberberine</title><description>The invention discloses novel application of epiberberine and an experimental method for inhibiting osteoclast differentiation induced by breast cancer cells. It is proved for the first time that epiberberine cannot inhibit proliferation of osteoclast precursor cells at a high concentration (25 [mu] M), and the epiberberine has high biological safety. In addition, epiberberine has a remarkable inhibition effect on osteoclast formation induced by breast cancer and osteolysis induced by metastatic breast cancer. 本发明公开了表小檗碱的新用途以及抑制乳腺癌细胞诱导破骨细胞分化的实验方法。本发明首次证明表小檗碱在较高浓度时(25μM)不会抑制破骨细胞前体细胞的增殖,其具有较高的生物安全性。另外,表小檗碱对乳腺癌诱导破骨细胞形成、以及转移性乳腺癌诱导的骨溶解具有显著的抑制作用。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJD3Sy1XSCwoyMlMTizJzM9TyE9TSC3ITEotAqLMvFQeBta0xJziVF4ozc2g6OYa4uyhm1qQH59aXJCYnJqXWhLv7GdoaGZhYGxsaeBoTIwaACWUJOM</recordid><startdate>20230926</startdate><enddate>20230926</enddate><creator>ZHANG FUMING</creator><creator>ZHANG XUENING</creator><creator>YANG YANCHAO</creator><creator>LIU JIACHEN</creator><creator>LIU BEIJIA</creator><creator>SHI MEINA</creator><creator>WEI CHENGMING</creator><creator>LIN, WAN-JIUN</creator><creator>MA WENZHE</creator><creator>HUANG ZIFENG</creator><creator>WANG ZI</creator><scope>EVB</scope></search><sort><creationdate>20230926</creationdate><title>New application of epiberberine</title><author>ZHANG FUMING ; ZHANG XUENING ; YANG YANCHAO ; LIU JIACHEN ; LIU BEIJIA ; SHI MEINA ; WEI CHENGMING ; LIN, WAN-JIUN ; MA WENZHE ; HUANG ZIFENG ; WANG ZI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN116803390A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHANG FUMING</creatorcontrib><creatorcontrib>ZHANG XUENING</creatorcontrib><creatorcontrib>YANG YANCHAO</creatorcontrib><creatorcontrib>LIU JIACHEN</creatorcontrib><creatorcontrib>LIU BEIJIA</creatorcontrib><creatorcontrib>SHI MEINA</creatorcontrib><creatorcontrib>WEI CHENGMING</creatorcontrib><creatorcontrib>LIN, WAN-JIUN</creatorcontrib><creatorcontrib>MA WENZHE</creatorcontrib><creatorcontrib>HUANG ZIFENG</creatorcontrib><creatorcontrib>WANG ZI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHANG FUMING</au><au>ZHANG XUENING</au><au>YANG YANCHAO</au><au>LIU JIACHEN</au><au>LIU BEIJIA</au><au>SHI MEINA</au><au>WEI CHENGMING</au><au>LIN, WAN-JIUN</au><au>MA WENZHE</au><au>HUANG ZIFENG</au><au>WANG ZI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>New application of epiberberine</title><date>2023-09-26</date><risdate>2023</risdate><abstract>The invention discloses novel application of epiberberine and an experimental method for inhibiting osteoclast differentiation induced by breast cancer cells. It is proved for the first time that epiberberine cannot inhibit proliferation of osteoclast precursor cells at a high concentration (25 [mu] M), and the epiberberine has high biological safety. In addition, epiberberine has a remarkable inhibition effect on osteoclast formation induced by breast cancer and osteolysis induced by metastatic breast cancer. 本发明公开了表小檗碱的新用途以及抑制乳腺癌细胞诱导破骨细胞分化的实验方法。本发明首次证明表小檗碱在较高浓度时(25μM)不会抑制破骨细胞前体细胞的增殖,其具有较高的生物安全性。另外,表小檗碱对乳腺癌诱导破骨细胞形成、以及转移性乳腺癌诱导的骨溶解具有显著的抑制作用。</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN116803390A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title New application of epiberberine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T17%3A55%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHANG%20FUMING&rft.date=2023-09-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN116803390A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true